Adverse events following Haemophilus influenzae type b vaccines in the vaccine adverse event reporting system, 1990-2013

Journal of Pediatrics

Volumn 166, Issue 4, 2015, Pages 992-997

  Moro, Pedro L ^a   Jankosky, Christopher ^b   Menschik, David ^b   Lewis, Paige ^a   Duffy, Jonathan ^a   Stewart, Brock ^a   Shimabukuro, Tom T ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B POLYSACCHARIDE VACCINE; HAEMOPHILUS VACCINE;

AGITATION; ANAPHYLAXIS; APNEA; ARTICLE; AUTOPSY; CAUSE OF DEATH; CONTROLLED CLINICAL TRIAL (TOPIC); CONVULSION; CRYING; DATA MINING; DEATH CERTIFICATE; DIARRHEA; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; FEBRILE CONVULSION; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HAEMOPHILUS INFLUENZAE TYPE B; HEALTH CARE PERSONNEL; HUMAN; INFANT; INFANT MORTALITY; INFLUENZA VACCINATION; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; INTUSSUSCEPTION; IRRITABILITY; LETHARGY; MALE; MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES; MUSCLE HYPOTONIA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RANDOM SAMPLE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SUDDEN INFANT DEATH SYNDROME; URTICARIA; VOMITING; BACTERIAL CAPSULE; BAYES THEOREM; CHILD; DRUG SURVEILLANCE PROGRAM; EPIDEMIOLOGY; FOLLOW UP; HAEMOPHILUS INFECTIONS; IMMUNOLOGY; MORTALITY; NEWBORN; PRESCHOOL CHILD; PROCEDURES; RETROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TRENDS; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BACTERIAL CAPSULES; BAYES THEOREM; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; INFANT; INFANT, NEWBORN; MALE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; UNITED STATES;

EID: 84931590676     PISSN: 00223476     EISSN: 10976833     Source Type: Journal    
DOI: 10.1016/j.jpeds.2014.12.014     Document Type: Article

References (37)

1. Centers for Disease Control and Prevention. FDA approval of use of a new haemophilus b conjugate vaccine and a combined diphtheria-tetanus-pertussis and haemophilus b conjugate vaccine for infants and children. MMWR Morb Mortal Wkly Rep 1993; 42:296-8.
2. Briere EC, Rubin L, Moro PL, Cohn A, Clark T, Messonnier N , Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC. Prevention and control of haemophilus influenzae type b disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63(RR-01):1-14.
3. Centers for Disease Control and Prevention. FDA approval for infants of a Haemophilus influenzae type b conjugate and hepatitis B (recombinant) combined vaccine. MMWR Morb Mortal Wkly Rep 1997;46: 107-9.
4. Centers for Disease Control and Prevention. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children. MMWR Morb Mortal Wkly Rep 2008;57:1079-80.
5. Centers for Disease Control and Prevention. Infant Meningococcal Vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep 2013;62:52-4.
6. Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992;120:184-9.
7. Fritzell B, Plotkin S. Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J Pediatr 1992;121:355-62.
8. Holmes SJ, Fritzell B, Guito KP, Esbenshade JF, Blatter MM, Reisinger KS, et al. Immunogenicity of Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine in infants. Am J Dis Child 1993;147:832-6.
9. Decker MD, Edwards KM, Bradley R, Palmer P. Responses of children to booster immunization with their primary conjugate Haemophilus influenzae type B vaccine or with polyribosylribitol phosphate conjugated with diphtheria toxoid. J Pediatr 1993;122:410-3.
10. Bryant KA, Marshall GS, Marchant CD, Pavia-Ruiz N, Nolan T, Rinderknecht S, et al. Immunogenicity and Safety of H. influenzae Type b-N meningitidis C/Y conjugate vaccine in Infants. Pediatrics 2011;127:e1375.
11. Black S, Greenberg DP. A combined diphtheria, tetanus, five-component acellular pertussis, poliovirus, and Haemophilus influenzae type b vaccine. Expert Rev Vaccines 2005;4:793-805.
12. Guerra FA, Blatter MM, Greenberg DP, Pichichero M, Noriega FR , Pentacel Study Group. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: A randomized, clinical trial. Pediatrics 2009;123: 301-12.
13. Rinderknecht S, Bryant K, Nolan T, Pavia-Ruz N, Doniz CA, Weber MA, et al. The safety profile of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (Hib-MenCY). Hum Vaccin Immunother 2012;8:1-8.
14. Davis RL, Black S, Shinefield H, Mahoney L, Zavitkovsky A, Lewis E, et al. Post-marketing evaluation of the short term safety of Comvax (R). Vaccine 2004;22:536-43.
15. Nelson JC, Yu O, Dominguez-Islas CP, Cook AJ, Peterson D, Greene SK, et al. Adapting group sequential methods to observational postlicensure vaccine safety surveillance: results of a pentavalent combination DTaPIPV-Hib vaccine safety study. Am J Epidemiol 2013;177:131-41.
16. Varricchio F, Iskander J, Destefano F, Ball R, Pless R, Braun MM. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004;23:287-94.
17. Medical Dictionary for Regulatory Activities, http://www.meddramsso. com/. Accessed August 19, 2014.
18. Food and Drug Administration. 21 CFR Part 600.80. Postmarketing reporting of adverse experiences. Fed Regist 1997;62:52252-3.
19. Vellozzi C, Broder KR, Haber P, Guh A, Nguyen M, Cano M, et al. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. Vaccine 2010;28:7248-55.
20. Rüggeberg JU, Gold MS, Bayas JM, Blum MD, Bonhoeffer J, Friedlander S, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine 2007;25:5675-84.
21. DuMouchel W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Stat 1999;53: 177-90.
22. Szarfman A, Machado SG, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Saf 2002;25:381-92.
23. Martin D, Menschik D, Bryant-Genevier M, Ball R. Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): A case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine. Drug Saf 2013;36:547-56.
24. Rudolph C, Rudolph A, Lister G, First L, Gershon A, eds. Rudolph's pediatrics. 22nd ed. New York: The McGraw-Hill Companies, Inc; 2011.
25. Leroy Z, Broder K, Menschik D, Shimabukuro T, Martin D. Febrile seizures after 2010-2011 influenza vaccine in young children, United States: A vaccine safety signal from the vaccine adverse event reporting system. Vaccine 2012;30:2020-3.
26. Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. Natl Vital Stat Rep 2013;61:1-116.
27. American Academy of Pediatrics Task Force on Sudden Infant Death Syndrome. The changing concept of sudden infant death syndrome: diagnostic coding shifts, controversies regarding the sleeping environment, and new variables to consider in reducing risk. Pediatrics 2005; 116:1245-55.
28. Centers for Disease Control and Prevention. Sudden Unexpected Infant Death and Sudden Infant Death Syndrome, http://www.cdc.gov/sids/; 2011. Accessed August 19, 2014.
29. Jorch G, Tapiainen T, Bonhoeffer J, Fischer TK, Heininger U, Hoet B , et al., Brighton Collaboration Unexplained Sudden Death Working Group. Unexplained sudden death, including sudden infant death syndrome (SIDS), in the first and second years of life: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007;25:5707-16.
30. Institute of Medicine. Immunization safety review: vaccinations and sudden unexpected death in infancy. Washington (DC): The National Academies Press; 2003.
31. Vennemann MM, Höffgen M, Bajanowski T, Hense HW, Mitchell EA. Do immunisations reduce the risk for SIDS? A meta-analysis. Vaccine 2007;25:4875-9.
32. Vennemann MM, Butterfass-Bahloul T, Jorch G, Brinkmann B, Findeisen M, Sauerland C , et al., GeSID Group. Sudden infant death syndrome: no increased risk after immunisation. Vaccine 2007;25:336-40.
33. Brotherton JM, Hull BP, Hayen A, Gidding HF, Burgess MA. Probability of coincident vaccination in the 24 or 48 hours preceding sudden infant death syndrome death in Australia. Pediatrics 2005;115:e643-6.
34. Silvers LE, Ellenberg SS, Wise RP, Varricchio FE, Mootrey GT, Salive ME. The epidemiology of fatalities reported to the vaccine adverse event reporting system 1990-1997. Pharmacoepidemiol Drug Saf 2001; 10:279-85.
35. Braun MM, Mootrey GT, Salive ME, Chen RT, Ellenberg SS. Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years' data from the Vaccine Adverse Event Reporting System (VAERS). Pediatrics 2000;106:E51.
36. Weintraub ES, Baggs J, Duffy J, Vellozzi C, Belongia EA, Irving S, et al. Risk of intussusception after monovalent rotavirus vaccination. N Engl J Med 2014;370:513-9.
37. Rates of Pertussis Disease Among Persons Receiving Pentacel or Other Pertussis Vaccines. ClinicalTrials.gov Identifier: NCT01129362, http:// clinicaltrials.gov/ct2/show/NCT01129362?term=pertussis&rank=3. Accessed August 19, 2014.